Pmv Pharmaceuticals Inc (PMVP)
Healthcare
Biotechnology
1.10 $
-1.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Pmv Pharmaceuticals Inc (PMVP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 80.9% of the shares are freely tradable; institutional investors hold 69.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
69.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
80.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
5.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
53Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BML Capital Management LLC | 9.98 | 5,320,000 | +0.5 | 03/31/2026 |
| TANG CAPITAL MANAGEMENT LLC | 7.96 | 4,245,085 | -14.1 | 03/31/2026 |
| Sio Capital Management, LLC | 5.77 | 3,076,580 | +16.7 | 03/31/2026 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 5.39 | 2,872,764 | -7.0 | 03/31/2026 |
| Euclidean Capital LLC | 4.93 | 2,627,643 | +0.0 | 03/31/2026 |
| Eversept Partners, LP | 4.40 | 2,348,360 | +0.0 | 03/31/2026 |
| Acadian Asset Management LLC | 4.15 | 2,215,894 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.07 | 2,170,310 | +0.3 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.70 | 1,974,906 | +0.0 | 03/31/2026 |
| Two Sigma Investments LLC | 3.53 | 1,884,530 | +166.9 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.